Fulgent Genetics Inc (FLGT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $688.98M
Last updated: Nov 17, 2026 at 4:30 PM ET
Fulgent Genetics Inc (FLGT) Stock Chart
Fulgent Genetics (FLGT) has a latest price of $24.21 on Nov 17, 2026, 22.0% below its 52-week high of $31.04. Its price fell 16.8% over the past 12 months. The month-end price rose 129.1% over the 10 years through Oct 2026, a compound annual rate of 8.6%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $110.49 in Jan 2021 and its lowest $3.17 in Dec 2018, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart FLGT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for FLGT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 22.6%, and over 6 months it rose 51.8%. The month-end price fell 13.9% over the 3 years through Oct 2026, a compound annual decline of 4.9%.
| Period | Change |
|---|---|
| 1 month | +20.4% |
| 3 months | +22.6% |
| 6 months | +51.8% |
| 12 months | -16.8% |
| 12 months, with dividends | -16.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -13.9% | -4.9% |
| 5 years | -75.1% | -24.3% |
| 10 years | +129.1% | +8.6% |
Price by Year
Its best calendar year was 2019, when the price rose 306.9%, and its weakest was 2022, when it fell 70.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $20.62 | -21.5% |
| 2025 | $26.27 | +42.2% |
| 2024 | $18.47 | -36.1% |
| 2023 | $28.91 | -2.9% |
| 2022 | $29.78 | -70.4% |
| 2021 | $100.59 | +93.1% |
| 2020 | $52.10 | +303.9% |
| 2019 | $12.90 | +306.9% |
| 2018 | $3.17 | -27.6% |
| 2017 | $4.38 | -62.1% |
Trading Range
The price is 12.4% above its 50-day average of $21.55 and 26.7% above its 200-day average of $19.11.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $24.21 | |
| 52-week high | $31.04 | -22.0% |
| 52-week low | $13.46 | +79.9% |
| 50-day average | $21.55 | +12.4% |
| 200-day average | $19.11 | +26.7% |
Price Risk
Over 3 years, its largest fall from a peak was 55.3%.
| Measure | Value |
|---|---|
| 1-year beta | 1.08 |
| Largest fall, 1 year | -55.3% |
| Largest fall, 3 years | -55.3% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About FLGT
What is FLGT's 1-year price change?
Fulgent Genetics's price fell 16.8% over the past 12 months. With dividends included, the 12-month total return was -16.8%.
What is FLGT's 5-year price change?
Fulgent Genetics's month-end price fell 75.1% over the 5 years through Oct 2026, a compound annual decline of 24.3%. These figures leave out dividends.
What is FLGT's 52-week high and low?
Fulgent Genetics's 52-week high is $31.04 and its 52-week low is $13.46. Its latest price of $24.21 on Nov 17, 2026 is 22.0% below the high.
What is FLGT's beta?
Fulgent Genetics's 1-year beta against the S&P 500 is 1.08, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 55.3%.
Is the FLGT chart free?
Yes. Advanced Charting for FLGT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
FLGT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts